View in EDS HTML Full Text

Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline

Saved in:
Bibliographic Details
Title: Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline
Authors: National Comprehensive Cancer Network
Source: Business Wire (English). 09/06/2012.
Abstract: The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded 11 research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate the clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced melanoma and other cancers. [ABSTRACT FROM PUBLISHER]
Database: Regional Business News
Full text is not displayed to guests.
FullText Text:
  Availability: 1
Header DbId: bwh
DbLabel: Regional Business News
An: bizwire.c43856287
AccessLevel: 6
PubType: News
PubTypeId: newspaperArticle
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22National+Comprehensive+Cancer+Network%22">National Comprehensive Cancer Network</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Business+Wire+%28English%29%22">Business Wire (English)</searchLink>. 09/06/2012.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) recently awarded 11 research grants to investigators following a review of proposals submitted in response to the NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4-million research grant from GlaxoSmithKline to scientifically evaluate the clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212) in treatment of advanced melanoma and other cancers. [ABSTRACT FROM PUBLISHER]
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=bwh&AN=bizwire.c43856287
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Researchers Receive Grants from NCCN Oncology Research Program Funded Through GlaxoSmithKline
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: National Comprehensive Cancer Network
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 06
              M: 09
              Text: 09/06/2012
              Type: published
              Y: 2012
          Titles:
            – TitleFull: Business Wire (English)
              Type: main
ResultId 1